Patient
SITE015-0037
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2025-10-13
Adverse events
8
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-10-17 (study day 181); relationship: NOT RELATED
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-09-10 (study day 144); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-09 (study day 112); relationship: RELATED
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-08 (study day 111); relationship: RELATED
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-07-13 (study day 85); relationship: not assessed
Grade 3 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-06-12 (study day 54); relationship: not assessed; serious criteria: hospitalization
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-11 (study day 53); relationship: NOT RELATED
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-16 (study day 27); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.